164 related articles for article (PubMed ID: 36104006)
21. Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer.
Xu J; Wang S; Zhong H; Zhang B; Qian J; Yang W; Qian F; Qiao R; Teng J; Lou Y; Zhang X; Chu T; Han B
Ann Thorac Surg; 2019 Jun; 107(6):1683-1689. PubMed ID: 30468727
[TBL] [Abstract][Full Text] [Related]
22. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
[TBL] [Abstract][Full Text] [Related]
23. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
24. Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer.
Xu Y; Wan B; Zhu S; Zhang T; Xie J; Liu H; Zhan P; Lv T; Song Y
Front Oncol; 2021; 11():784289. PubMed ID: 35155190
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy.
Qian J; Xu J; Wang S; Qian F; Yang W; Zhang B; Zhang Y; Nie W; Lou Y; Lu J; Zhang X; Zhang W; Chu T; Zhong H; Fang W; Zhao H; Han B
Ann Surg Oncol; 2019 Aug; 26(8):2392-2400. PubMed ID: 31011907
[TBL] [Abstract][Full Text] [Related]
26. Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model.
Jang HJ; Cho S; Kim K; Jheon S; Yang HC; Kim DK
Cancer Res Treat; 2017 Oct; 49(4):898-905. PubMed ID: 28111426
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
28. The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma.
Yang L; Zhang J; Yang G; Xu H; Lin J; Shao L; Li J; Guo C; Du Y; Guo L; Li X; Han-Zhang H; Wang C; Chuai S; Ye J; Kang Q; Liu H; Ying J; Wang Y
Theranostics; 2020; 10(17):7635-7644. PubMed ID: 32685009
[TBL] [Abstract][Full Text] [Related]
29. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
Park BJ; Cho JH; Lee JH; Shin S; Kim HK; Choi YS; Zo JI; Shim YM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K; Kim J
Lung Cancer; 2018 Mar; 117():7-13. PubMed ID: 29496256
[TBL] [Abstract][Full Text] [Related]
30. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA; Neal JW; Chaft JE; Azzoli CG; Jänne PA; Govindan R; Evans TL; Costa DB; Wakelee HA; Heist RS; Shapiro MA; Muzikansky A; Murthy S; Lanuti M; Rusch VW; Kris MG; Sequist LV
J Clin Oncol; 2019 Jan; 37(2):97-104. PubMed ID: 30444685
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
32. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
Mizuno T; Ishii G; Nagai K; Yoshida J; Nishimura M; Mochizuki T; Kawai O; Hasebe T; Ochiai A
Lung Cancer; 2008 Dec; 62(3):302-8. PubMed ID: 18486987
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma.
Brandt WS; Bouabdallah I; Tan KS; Park BJ; Adusumilli PS; Molena D; Bains MS; Huang J; Isbell JM; Bott MJ; Jones DR
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1212-1224.e3. PubMed ID: 29246549
[TBL] [Abstract][Full Text] [Related]
34. [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].
Shen C; Fang W
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):593-600. PubMed ID: 36002196
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion.
Wang S; Xu J; Wang R; Qian F; Yang W; Qiao R; Zhang B; Qian J; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Nov; 156(5):2006-2015.e2. PubMed ID: 30104070
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
37. Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Zhai X; Yang L; Chen S; Zheng Q; Wang Z
Cancer Med; 2016 Sep; 5(9):2286-93. PubMed ID: 27367482
[TBL] [Abstract][Full Text] [Related]
38. Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB-IIA Lung Adenocarcinoma.
Zhai W; Gong L; Zheng Y; Yan Q; Lai R; Liang D; Wong W; Dai S; Wang J
Front Oncol; 2022; 12():851276. PubMed ID: 35402251
[TBL] [Abstract][Full Text] [Related]
39. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
40. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
